Parabilis Sets Record $670M Biotech IPO; Sanofi Halts Riliprubart Phase 3

Takeda's zasocitinib just beat Bristol Myers' Sotyktu in a head-to-head Phase 3 — thirty-five percent complete skin clearance at sixteen weeks, more than two and a half times the Sotyktu rate.

Summit pulls a five hundred million dollar share offering after one day, Genentech axes three VPs and shutters infectious disease research, and Novartis notches a win from the twelve billion dollar Avidity platform. Thursday, June eleventh.

Welcome to The Pharma Closeout for Thursday, June eleventh, twenty twenty-six. I'm Alex Mercer.

And I'm Maya Patel. Let's get into it.

Top story. Takeda just put a definitive marker down in the TYK2 space. The LATITUDE Atlas trial — their head-to-head Phase 3 pitting zasocitinib against Bristol Myers' Sotyktu in plaque psoriasis — hit its primary endpoint with statistical superiority on PASI 100 response at week sixteen. Per Reuters, zasocitinib achieved complete skin clearance in thirty-five percent of patients — more than two and a half times the rate seen with Sotyktu in the same study.

The selectivity story is what makes this more than a topline beat. Zasocitinib delivers more than a million-fold selectivity for TYK2 over JAK1, 2, and 3 based on in vitro data — that's the kind of margin that keeps this molecule entirely outside the ORAL Surveillance safety overhang. For BMS, this isn't just share erosion in dermatology. Sotyktu was positioned as the clean oral alternative to biologics, and a direct competitor just outperformed it on the efficacy endpoint prescribers weight most heavily.

Takeda has been calling zasocitinib a four billion dollar commercial opportunity. That's ambitious for a second oral entrant in a space still dominated by injectable biologics. But a head-to-head superiority claim is the single most powerful tool for breaking prescribing inertia — it's the one data point reps can lead with in every call.

Four billion is a steep number for a molecule that still needs to demonstrate long-term durability and safety at scale. The biologic incumbents have years of real-world evidence and entrenched formulary positions — one Phase 3 win doesn't knock that wall down.

Fair point. The biologic moat is real, and you don't unseat formulary incumbents with one study. But oral convenience is a structural advantage that compounds over time — patients and prescribers both prefer a pill when efficacy is comparable. If zasocitinib holds at biologic-adjacent clearance levels, the switching conversation starts faster than BMS would like.

What I'd focus on more closely is the BMS side. We've been tracking Sotyktu for months on this show. Despite being the only approved oral TYK2 inhibitor, the drug has underperformed commercially. Now layer a head-to-head loss on top of that, and the prescriber narrative flips from first oral TYK2 option to the one that lost the head-to-head. That reframing is very hard to reverse once it sets in.

Takeda says the NDA filing is on track for the current fiscal year. What BMS does between now and that filing tells you whether they're defending Sotyktu or quietly reallocating immunology resources to other assets.

And the bigger read-through goes beyond psoriasis. If zasocitinib's selectivity profile and efficacy translate across additional inflammatory indications, Takeda isn't launching a dermatology drug — they're building a platform franchise. That's where the four-billion-dollar thesis lives or dies. Investors won't be pricing psoriasis market share alone — they'll be pricing optionality across immunology.

Platform value is exactly the lens for our next story. Novartis reported Thursday that an antibody-oligonucleotide conjugate from the twelve billion dollar Avidity Biosciences acquisition posted positive biomarker results in facioscapulohumeral muscular dystrophy. This is the proof-of-concept milestone Novartis needed to show the platform can deliver beyond the lead Duchenne program.

AOCs use an antibody as a delivery vehicle to get RNA payloads directly into target tissues — in this case, skeletal muscle. The FSHD readout is the critical second data point for the Avidity thesis. Platform technologies either demonstrate reproducibility or they don't — and at twelve billion dollars, Novartis needed del-brax to work across muscular dystrophy subtypes. Biomarker responses are encouraging, but they still need to translate into functional improvement before this moves from proof-of-concept to a commercial narrative.

Meanwhile, the capital markets told two very different stories in the span of twenty-four hours. Kardigan set IPO terms Thursday with pricing in the mid-range, targeting significant capital raise and a substantial valuation. This cardiac drugmaker would be among the year's biotech IPOs, coming shortly after Parabilis achieved a notable fundraising milestone. But Summit Therapeutics pulled its five hundred million dollar secondary offering after just one day, citing market conditions.

Same market, opposite outcomes, on consecutive days. New stories with clean narratives are getting funded. Existing names that haven't broken out on their milestones are getting passed over. That's a filter, not a coincidence — and it tightens as long as the macro backdrop stays this uncertain.

Couple of quick pipeline hits. J&J released Phase 2/3 data from the ENERGY study for Imaavy — nipocalimab — in warm autoimmune hemolytic anemia, showing durable hemoglobin improvement and reduced steroid use. Per J&J's announcement, wAIHA currently has no FDA-approved therapies — positioning this as a potential label expansion into genuinely untreated territory.

FcRn blockade in wAIHA targets pathogenic IgG recycling directly rather than going through B-cell depletion and waiting for autoantibody titers to fall. If the data supports a filing, J&J adds another indication to the nipocalimab franchise beyond myasthenia gravis.

Ethyreal launched with a hundred and one million dollars targeting thyroid eye disease and Graves' disease — stepping into Tepezza territory with what the company describes as a differentiated mechanism and a dual-indication approach. And Teva detailed further workforce reductions as its restructuring continues — cuts the generics giant has been telegraphing for months, now arriving in specifics. Maya, on the regulatory side — a couple of setbacks and a major shakeup.

Start with Camurus. The FDA issued a second Complete Response Letter for Oclaiz — their long-acting octreotide formulation CAM2029 — in acromegaly. The PDUFA date was yesterday. Two CRLs for the same program typically mean the deficiencies from round one weren't resolved to FDA's satisfaction. For a company of Camurus's size in a niche endocrine market, each resubmission cycle burns capital and credibility. The path from here narrows considerably.

Small market, high bar, two rejections. At some point the resubmission math stops working.

Separately, Sensorion dropped its gene therapy for OTOF-related hearing loss after a strategic review concluded the competitive environment had — and I'm quoting — notably changed. They specifically named Regeneron's expanding presence in genetic hearing loss as the driver and are pivoting to a different program entirely.

Regeneron is effectively consolidating the genetic hearing loss space before it's fully established. Smaller competitors are being forced to make triage decisions they probably hoped to defer by a year or two.

And then Genentech. Another round of layoffs — three VPs dismissed, including Vishva Dixit, who has been at the company for nearly thirty years and is one of the most recognized names in immunology research. The infectious disease research unit has reportedly been shuttered entirely. Losing someone of Dixit's stature isn't a restructuring footnote — it's a statement about which therapeutic areas Roche's U.S. research arm considers core going forward. Infectious disease, it appears, is no longer one of them.

Looking ahead. Takeda's NDA filing timeline for zasocitinib — they've committed to this fiscal year, and after today's head-to-head data, expect them to move aggressively on submission. Kardigan's IPO should price imminently — after Parabilis's record haul and Summit's withdrawal, this one is a real-time read on how selective the biotech capital window has gotten. And Astellas' CEO laid out plans today for offsetting the Xtandi patent cliff — we'll be tracking which pipeline assets and deal targets they're leaning on to fill a multibillion-dollar revenue gap.

Keep the macro in frame. May CPI printed at four point two percent year-over-year — hottest reading since April twenty twenty-three — and Fed-hike odds are surging. That matters directly for every biotech financing story we track. If rates stay elevated, the funding filter only tightens — and the gap between well-capitalized companies and everyone else keeps widening. That's the backdrop for every deal and IPO we'll cover through the summer.

That's your Pharma Closeout for Thursday. Takeda redrawing the TYK2 competitive map with zasocitinib, Novartis proving the Avidity platform works beyond Duchenne, the IPO market picking winners with surgical precision, and Genentech reshaping Roche's research footprint. Big stories, real implications. If this briefing saves you time, follow us on Spotify and drop a rating — it helps other pharma professionals find the show. We'll be back tomorrow.

Busy day. Have a great Thursday evening — see you tomorrow. ### Episode Metadata **Title:** Takeda Zasocitinib Beats Sotyktu in Head-to-Head Phase 3; Summit Pulls $500M Offering; Novartis Avidity Trial Win | Jun 11, 2026 **Description:** Zasocitinib hits 35% complete skin clearance at week 16, topping Sotyktu by more than 2.5x in Takeda's head-to-head Phase 3. Plus: Novartis validates its $12B Avidity AOC platform in FSHD, Summit withdraws $500M offering, and Genentech reshapes its research organization. **Tags:** zasocitinib, Takeda, Sotyktu, deucravacitinib, Bristol Myers Squibb, TYK2, plaque psoriasis, PASI 100, Novartis, Avidity Biosciences, AOC, muscular dystrophy, FSHD, Summit Therapeutics, ivonescimab, Kardigan, IPO, J&J, nipocalimab, Imaavy, wAIHA, Genentech, Roche, Vishva Dixit, Camurus, Oclaiz, acromegaly, CRL, Sensorion, Regeneron, hearing loss, Ethyreal, thyroid eye disease, Teva, Astellas, Xtandi, pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals #